CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 98 enrolled
Drug / intervention
BI 113608 +7 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01922349
NCT01922349Phase 1Completed

Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses and Multiple Rising Oral Doses of BI 113608 in Healthy Male Asian and Caucasian Volunteers (Randomised, Double-blind, Placebo-controlled Within Dose Groups)

Boehringer Ingelheim·interventional·Posted Aug 14, 2013·Updated Jan 20, 2017

In Brief

A Phase 1 clinical trial evaluating BI 113608 and Placebo for Healthy. Completed, enrolled 98 participants across 1 site.

Detailed Summary

Safety, tolerability and pharmacokinetics of single and multiple oral doses of BI 113608 in healthy Chinese, Japanese and Caucasian male volunteers.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesSouth Korea
Collaborators--

Timeline

Phase 1CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedAug 14, 2013
Enrollment StartAug 1, 2013
Primary CompletionMay 1, 2014
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 12.9 years ago

Interventions

BI 113608drug

Medium dose (Multiple dosing)

Placebodrug

Placebo (Multiple dosing)

BI 113608drug

Low dose (Multiple dosing)

Placebodrug

Placebo (Single dosing)

BI 113608drug

High dose (Single dosing)

BI 113608drug

Medium dose (Single dosing)

BI 113608drug

Low dose (Single dosing)

BI 113608drug

High dose (Multiple dosing)